Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ORGANIZATION
ORGANIZATION
- Drug Pricing Subcommittee President Bessho Calls for Correction in “Across-the-Board” Bundling
December 15, 2011
- Drug Expenditure Ratio Should Be Fixed: Professor Endo, Gakushuin University
December 15, 2011
- Industry Reps Call for 4-6 Year Extension of Trial for Premium for New Drug Development
December 15, 2011
- Share of Generics Virtually Unchanged at 23.2%: JGA Flash Report
December 14, 2011
- 129 Hospitals Stopped Providing Services in Ophthalmology Since 2008: JOA
December 13, 2011
- JMA Announces View on TPP Agreement on Website
December 12, 2011
- Osaka Bio Fund Chooses Tokyo Drug Discovery Venture as No. 3 Investment Project
December 9, 2011
- JACDS Engaged in Petition Drive to Prevent Ban on “Dispensing Point” Services
December 9, 2011
- Shortest Development, Review Periods for New Drugs in 2010: OPIR Report
December 8, 2011
- FBRI to Open Nation’s Biggest Manufacturing Facility for Investigational PET Drugs
December 7, 2011
- PSUR to Be Renamed PBRER: ICH
December 5, 2011
- JACDS Council Holds Hearings on Remote Sales of OTC Drugs
December 2, 2011
- Original Drug Makers Should Let Go of Long-Listed Drugs
December 1, 2011
- Early Exploratory Studies Should Be Conducted in Japan for Japan-originated New Drugs: FPMAJ Chairman Shoda
December 1, 2011
- HGPI Holds Forum on Global Measures for NCD Issues
November 30, 2011
- Japanese Respiratory Foundation to Promote Research, Awareness of Respiratory Diseases
November 30, 2011
- Economic Losses Due to Illness, Injury Total ¥3.3 Tril. Annually in Japan: ACCJ
November 28, 2011
- MSF Japan General Director Expresses Concern Over TPP Negotiations, Possible Generics Price Rise
November 25, 2011
- SAMURAI Biotech Association Presents Petition to Health Minister Calling for NHI Pricing System Reflecting Economic Assessment
November 25, 2011
- JPMA, FPMAJ Call on LDP Council on Budget and Tax System with Requests for Next Year
November 24, 2011
ページ
Japan’s health and finance ministers agreed late last year to go ahead with an “off-year” drug price revision in FY2027,…
The Japanese healthcare sector is experiencing rapid growth, demanding a highly skilled and diverse workforce. However, finding and attracting the best talent in this competitive market presents significant challenges.Enter AI. With the rise of AI-powered tools, healthcare organizations can revolutionize…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…